Free Trial
NYSE:CLDI

Calidi Biotherapeutics (CLDI) Stock Price, News & Analysis

Calidi Biotherapeutics logo
$1.68 -0.03 (-1.46%)
As of 10:43 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Calidi Biotherapeutics Stock (NYSE:CLDI)

Key Stats

Today's Range
$1.68
$1.74
50-Day Range
$1.56
$11.98
52-Week Range
$1.54
$46.68
Volume
58,608 shs
Average Volume
644,932 shs
Market Capitalization
$5.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Calidi Biotherapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
31st Percentile Overall Score

CLDI MarketRank™: 

Calidi Biotherapeutics scored higher than 31% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Calidi Biotherapeutics.

  • Earnings Growth

    Earnings for Calidi Biotherapeutics are expected to grow in the coming year, from ($4.48) to ($0.88) per share.

  • Percentage of Shares Shorted

    24.18% of the float of Calidi Biotherapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Calidi Biotherapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Calidi Biotherapeutics has recently decreased by 81.25%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Calidi Biotherapeutics does not currently pay a dividend.

  • Dividend Growth

    Calidi Biotherapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    24.18% of the float of Calidi Biotherapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Calidi Biotherapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Calidi Biotherapeutics has recently decreased by 81.25%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Calidi Biotherapeutics has a news sentiment score of 1.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Calidi Biotherapeutics this week, compared to 1 article on an average week.
  • Search Interest

    Only 2 people have searched for CLDI on MarketBeat in the last 30 days. This is a decrease of -91% compared to the previous 30 days.
  • MarketBeat Follows

    5 people have added Calidi Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Calidi Biotherapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $455,000.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 6.70% of the stock of Calidi Biotherapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 12.53% of the stock of Calidi Biotherapeutics is held by institutions.

  • Read more about Calidi Biotherapeutics' insider trading history.
Receive CLDI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Calidi Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CLDI Stock News Headlines

INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.tc pixel
Calidi Biotherapeutics Secures FDA Fast Track Designation
See More Headlines

CLDI Stock Analysis - Frequently Asked Questions

Calidi Biotherapeutics' stock was trading at $13.80 at the beginning of 2025. Since then, CLDI shares have decreased by 87.6% and is now trading at $1.71.

Calidi Biotherapeutics, Inc. (NYSE:CLDI) announced its quarterly earnings data on Tuesday, November, 12th. The company reported ($7.80) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($10.20) by $2.40.

Shares of Calidi Biotherapeutics reverse split before market open on Monday, July 15th 2024.The 1-10 reverse split was announced on Monday, July 15th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, July 15th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Top institutional investors of Calidi Biotherapeutics include Armistice Capital LLC (26.17%), Bank of Montreal Can (1.16%), Geode Capital Management LLC (7.69%) and Quaker Wealth Management LLC. Insiders that own company stock include Scott Leftwich, Eric E Poma and Allan Camaisa.
View institutional ownership trends
.

Shares of CLDI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Calidi Biotherapeutics investors own include ARMOUR Residential REIT (ARR), AGNC Investment (AGNC), Avino Silver & Gold Mines (ASM), Carlyle Secured Lending (CGBD), Devon Energy (DVN), Hercules Capital (HTGC) and Main Street Capital (MAIN).

Company Calendar

Last Earnings
11/12/2024
Today
8/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSE:CLDI
Previous Symbol
NYSE:CLDI
CIK
1855485
Fax
N/A
Employees
38
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$29.22 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-344.45%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.19
Quick Ratio
0.19

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($2.32) per share
Price / Book
-0.74

Miscellaneous

Outstanding Shares
3,426,000
Free Float
20,039,000
Market Cap
$5.86 million
Optionable
N/A
Beta
1.15

Social Links

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NYSE:CLDI) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners